N-Zyme Biomedical Closes US$4.6 Million Series A Financing to Advance Clinical Development
N-Zyme Biomedical today announced the successful closing of its Series A financing, raising approximately US$4.6 million to accelerate the advancement of its Phase 2 clinical programs and further the development of its novel pepsin inhibitor platform for reflux disease.
N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease
N-Zyme Biomedical, a clinical-stage biotechnology company developing a novel class of therapeutics targeting pepsin in reflux disease, today announced the initiation of its Phase 2 clinical trial to evaluate its lead pepsin inhibitor candidate for the treatment of laryngopharyngeal reflux (LPR).
